AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Company is awarded patent covering GLQ223. (anti-AIDS drug alpha-trichosanthin) (Genelabs Technologies Inc.)
Genelabs Technologies Inc.
Genelabs Technologies Inc., Redwood City, California, announced that it has been awarded a U.S. patent associated with the development of its anti-AIDS drug, GLQ223 (alpha-trichosanthin).
The patent covers a gene sequence encoding trichosanthin, as well as vectors to produce recombinant versions of this molecule. Use of trichosanthin and the family of related molecules in the treatment of AIDS is also covered by U.S. patents previously awarded to Genelabs in 1989.
"The patented technology ensures that we have a genetically engineered source for development and commercialization of this product," stated Frank F.C. …
-
- Genelabs Technologies and Tanabe Seiyaku enter into collaboration and licence...
-
News wire article from: Asia Africa Intelligence Wire
January 28, 2004
700+ words
-
- Press Release: Genelabs Technologies and Patheon enter into commercial supply...
-
News wire article from: Asia Africa Intelligence Wire
September 19, 2002
700+ words
-
- Press Release: Genelabs Technologies presents antifungal research at the 41st...
-
News wire article from: Chemical Business Newsbase
December 17, 2001
700+ words
-
- Genelabs Technologies reports 2006 year-end and 4Q 2006 financial results. [2...
-
News wire article from: Chemical Business Newsbase
March 22, 2007
700+ words
-
- Genelabs files a $39 million stock offering; biotech company, working on...
-
Magazine article from: San Francisco Business Times
Nelson, Eric
May 3, 1991
700+ words
